The role of aldosterone and ideal cardiovascular health in incident cardiovascular disease: The Jackson heart study.
Aldosterone
Cardiovascular disease
Ideal cardiovascular health
Journal
American journal of preventive cardiology
ISSN: 2666-6677
Titre abrégé: Am J Prev Cardiol
Pays: Netherlands
ID NLM: 101769122
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
16
09
2022
revised:
31
03
2023
accepted:
01
04
2023
medline:
28
4
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Higher levels of ideal cardiovascular health (ICH) are associated with lower levels of aldosterone and incidence of cardiovascular disease (CVD). However, the degree to which aldosterone mediates the association between ICH and CVD incidence has not been explored. Thus, we investigated the mediational role of aldosterone in the association of 5 components of ICH (cholesterol, body mass index (BMI), physical activity, diet and smoking) with incident CVD and the mediational role of blood pressure (BP) and glucose in the association of aldosterone with incident CVD in a cohort of African Americans (AA). The Jackson Heart Study is a prospective cohort of AAs adults with data on CVD outcomes. Aldosterone, ICH metrics and baseline characteristics were collected at exam 1 (2000-2004). ICH score was developed by summing 5 ICH metrics (smoking, dietary intake, physical activity, BMI, and total cholesterol) and grouped into two categories (0-2 and ≥3 metrics). Incident CVD was defined as stroke, coronary heart disease, or heart failure. Cox proportional hazard regression models were used to model the association of categorical ICH score with incident CVD. The R Package Among 3,274 individuals (mean age: 54±12.4 years, 65% female), there were 368 cases of incident CVD over a median of 12.7 years. The risk of incident CVD was 46% lower (HR: 0.54; 95%CI 0.36, 0.80) in those with ≥3 ICH metrics at baseline compared to 0-2. Aldosterone mediated 5.4% ( Aldosterone partially mediates the association of ICH with incident CVD and both blood pressure and glucose partially mediate the association of aldosterone with incident CVD, emphasizing the potential importance of aldosterone and ICH in risk of CVD among AAs.
Sections du résumé
Background
UNASSIGNED
Higher levels of ideal cardiovascular health (ICH) are associated with lower levels of aldosterone and incidence of cardiovascular disease (CVD). However, the degree to which aldosterone mediates the association between ICH and CVD incidence has not been explored. Thus, we investigated the mediational role of aldosterone in the association of 5 components of ICH (cholesterol, body mass index (BMI), physical activity, diet and smoking) with incident CVD and the mediational role of blood pressure (BP) and glucose in the association of aldosterone with incident CVD in a cohort of African Americans (AA).
Methods
UNASSIGNED
The Jackson Heart Study is a prospective cohort of AAs adults with data on CVD outcomes. Aldosterone, ICH metrics and baseline characteristics were collected at exam 1 (2000-2004). ICH score was developed by summing 5 ICH metrics (smoking, dietary intake, physical activity, BMI, and total cholesterol) and grouped into two categories (0-2 and ≥3 metrics). Incident CVD was defined as stroke, coronary heart disease, or heart failure. Cox proportional hazard regression models were used to model the association of categorical ICH score with incident CVD. The R Package
Results
UNASSIGNED
Among 3,274 individuals (mean age: 54±12.4 years, 65% female), there were 368 cases of incident CVD over a median of 12.7 years. The risk of incident CVD was 46% lower (HR: 0.54; 95%CI 0.36, 0.80) in those with ≥3 ICH metrics at baseline compared to 0-2. Aldosterone mediated 5.4% (
Conclusion
UNASSIGNED
Aldosterone partially mediates the association of ICH with incident CVD and both blood pressure and glucose partially mediate the association of aldosterone with incident CVD, emphasizing the potential importance of aldosterone and ICH in risk of CVD among AAs.
Identifiants
pubmed: 37114212
doi: 10.1016/j.ajpc.2023.100494
pii: S2666-6677(23)00035-1
pmc: PMC10126856
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100494Informations de copyright
© 2023 The Authors. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Circulation. 2015 Dec 1;132(22):2134-45
pubmed: 26362633
J Am Heart Assoc. 2017 Oct 17;6(10):
pubmed: 29042430
Ann Intern Med. 2009 Jun 2;150(11):776-83
pubmed: 19487712
J Am Coll Cardiol. 2011 Apr 19;57(16):1690-6
pubmed: 21492767
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
Ethn Dis. 2005 Autumn;15(4 Suppl 6):S6-4-17
pubmed: 16320381
NCHS Data Brief. 2017 Dec;(293):1-8
pubmed: 29319473
J Epidemiol Community Health. 2021 Jan;75(1):92-99
pubmed: 32892156
Sci China Life Sci. 2018 May;61(5):504-514
pubmed: 29721777
Obes Res. 1999 Jul;7(4):355-62
pubmed: 10440591
J Am Heart Assoc. 2017 Jun 21;6(6):
pubmed: 28637777
Circulation. 2012 Jun 19;125(24):2975-84
pubmed: 22619283
Circulation. 2015 Nov 10;132(19):1825-33
pubmed: 26432671
J Am Coll Cardiol. 1999 Oct;34(4):1170-5
pubmed: 10520808
Exp Physiol. 2007 Sep;92(5):871-9
pubmed: 17483200
Cell Tissue Res. 2012 Apr;348(1):71-80
pubmed: 22331364
Hypertension. 2012 May;59(5):1069-78
pubmed: 22493070
Public Health Nutr. 2005 Feb;8(1):87-96
pubmed: 15705249
Am Heart J. 2010 Oct;160(4):744-51
pubmed: 20934570
Diabetologia. 2016 Sep;59(9):1893-903
pubmed: 27272340
Int J Cardiol. 2016 Jul 1;214:279-83
pubmed: 27085116
J Am Heart Assoc. 2018 Sep 4;7(17):e009890
pubmed: 30371168
Ethn Dis. 2005 Autumn;15(4 Suppl 6):S6-49-55
pubmed: 16317985
Nat Rev Nephrol. 2013 Aug;9(8):459-69
pubmed: 23774812
Hypertension. 2008 Feb;51(2):161-7
pubmed: 18172061
Am J Prev Cardiol. 2023 Jan 15;13:100466
pubmed: 36798725
Am J Prev Med. 2016 Oct;51(4):502-6
pubmed: 27539974
Biochem Biophys Res Commun. 2009 Dec 25;390(4):1208-13
pubmed: 19878661
Curr Hypertens Rep. 2003 Apr;5(2):106-9
pubmed: 12642008
Med Sci Sports Exerc. 2000 Jul;32(7):1327-38
pubmed: 10912901
Curr Hypertens Rep. 2013 Feb;15(1):59-70
pubmed: 23242734
J Endocrinol. 2017 Feb;232(2):R115-R129
pubmed: 27913572
Prostaglandins Leukot Essent Fatty Acids. 1999 May-Jun;60(5-6):401-5
pubmed: 10471129
Scand J Prim Health Care. 2017 Dec;35(4):322-328
pubmed: 29096579
J Clin Endocrinol Metab. 2016 Apr;101(4):1770-8
pubmed: 26908112
Adv Exp Med Biol. 2015;837:57-66
pubmed: 25310950
J Hum Hypertens. 2015 Jan;29(1):53-7
pubmed: 24785976
Mayo Clin Proc. 2018 Nov;93(11):1589-1599
pubmed: 30274906
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
JACC Heart Fail. 2017 Sep;5(9):642-651
pubmed: 28822744
Circ Heart Fail. 2017 Feb;10(2):
pubmed: 28209767
Endocrinology. 2011 Mar;152(3):751-63
pubmed: 21239432
Nutrients. 2019 Apr 26;11(5):
pubmed: 31035479
Circulation. 2012 Jul 3;126(1):50-9
pubmed: 22693351
JAMA. 2012 Mar 28;307(12):1273-83
pubmed: 22427615
Am J Clin Nutr. 1982 Nov;36(5):936-42
pubmed: 7137077
Endocrinol Jpn. 1987 Oct;34(5):635-45
pubmed: 2830099
Am J Prev Med. 2017 Nov;53(5):e165-e174
pubmed: 28818415
Ethn Dis. 2005 Autumn;15(4 Suppl 6):S6-62-70
pubmed: 16317987
Clin Pharmacol Ther. 1988 Oct;44(4):426-30
pubmed: 3048842
Nat Rev Endocrinol. 2010 Feb;6(2):83-93
pubmed: 20027193
Am J Med. 1985 Apr;78(4):564-8
pubmed: 2984931
Am J Med Sci. 2004 Sep;328(3):131-44
pubmed: 15367870